ライフサイエンスコーパス: bone tumor

1 Osteosarcoma is a primary malignant bone tumor.

2 clinical outcomes in the surgical removal of bone tumor.

3 blation has been widely accepted in treating bone tumor.

4 microwave-induced hyperthermia to remove the bone tumor.

5 s the second most common malignant pediatric bone tumor.

6 al study is the survivors of lower-extremity bone tumors.

7 er than 8 cm in diameter, and 26 had primary bone tumors.

8 imb salvage procedures for primary malignant bone tumors.

9 esions from more common, aggressive temporal bone tumors.

10 en, and only two of the G2A-R mice developed bone tumors.

11 hat SV40-like sequences are present in human bone tumors.

12 easing role in the percutaneous treatment of bone tumors.

13 ous applications, including visualization of bone tumors.

14 that reported in contemporary PDB-associated bone tumors.

15 ded 667 benign bone tumors and 267 malignant bone tumors.

16 rosthetic reconstruction for lower extremity bone tumors.

17 efficacy of anticancer drugs when combating bone tumors.

18 to be effective in the management of painful bone tumors.

19 bone-targeting moieties for the treatment of bone tumors.

20 tion (RFA) is effective in the management of bone tumors.

21 sions that have similarities to human FD and bone tumors.

22 activity and did not affect the phenotype of bone tumors.

23 heir indications to the treatment of primary bone tumors.

24 odality therapy for the treatment of primary bone tumors.

25 analyzable in 316 patients: 183 had primary bone tumors; 133 had primary soft-tissue tumors.

26 CNS tumors (9.5%; 95% CI, 5.2% to 13.8%) and bone tumors (8.1%; 95% CI, 5.1% to 11.1%) had the highes

27 beled targeted Pam-NPs demonstrated enhanced bone tumor accumulation and prolonged retention compared

28 is the second most common primary malignant bone tumor and highly resistant to conventional chemothe

29 internal data set, which included 667 benign bone tumors and 267 malignant bone tumors.

30 vivo models for investigating human primary bone tumors and cancer metastasis to the bone rely on th

31 ave proved effective for treatment of benign bone tumors and for palliation of metastases involving b

32 a is a heterogeneous collection of malignant bone tumors and is the second most common primary malign

33 steolysis associated with inoperable primary bone tumors and multifocal skeletal metastases remains a

34 FGF9-neutralizing antibody developed smaller bone tumors and reduced bone formation.

35 ems to be of benefit in T-staging of primary bone tumors and soft-tissue sarcomas.

36 the major surgical approaches to lower-limb bone tumors and their impact on pediatric patients.

37 acture, basilar impression, spinal stenosis, bone tumor, and osteoarthrosis.

38 curred both in vivo in experimental prostate bone tumors, and in vitro in co-cultures of bone marrow

39 proved specificity and efficacy for treating bone tumors are highly needed.

40 81, 96) specificity in the classification of bone tumors as malignant or benign.

41 These include primary bone tumors as well as metastatic disease from distant p

42 treated versus untreated metastatic prostate bone tumors at 7 days post treatment initiation (P < 0.0

43 mportant clinical factor in the diagnosis of bone tumors, because various lesions have predilections

44 oblastoma, soft-tissue sarcoma, or malignant bone tumor before the age of 21 years and who survived a

45 nt cryoablation of 320 primary or metastatic bone tumors between January 2008 and November 2017.

46 disability include an original diagnosis of bone tumor, brain tumor, or Hodgkin's disease; female se

47 ng in breast cancer cells therefore promotes bone tumor burden and tumor-mediated osteolysis through

48 e chemotherapeutic docetaxel, we showed that bone tumor burden could be reduced significantly with le

49 C)-mediated T-cell activation, had increased bone tumor burden despite protection from bone loss.

50 In a model of tumor metastasis to bone, bone tumor burden was decreased in the CD47(-/-) mice co

51 gulates processes associated with osteolytic bone tumor burden, we stably infected the bone-seeking M

52 To invade the bone, tumor cells produce osteoclast-activating factors

53 bone cyst (ABC) is an aggressive, pediatric bone tumor characterized by extensive destruction of the

54 Osteosarcoma (OS) is the most common bone tumor characterized with a high risk of amputation

55 he approach to the radiographic diagnosis of bone tumors consists of analyzing the lesion in an organ

56 Primary bone tumors constitute 1-1.5% of all tumors, and 7% of a

57 ion of the tumors reveals that the FBR v-fos bone tumors contain malignant cells with features of fou

58 Conclusion Bone tumor cryoablation is safe, with a 2.5% rate of maj

59 ication rate and associated risk factors for bone tumor cryoablation.

60 ors may have efficacy in treating metastatic bone tumors dependent on the CXCL5/CXCR2 axis.

61 udy of osteosarcoma (OS), a highly malignant bone tumor diagnosed in approximately 1000 pediatric/ado

62 ance in selected cases--for example, primary bone tumors, early bone marrow infiltration, and tumors

63 long-term complications in primary malignant bone tumors for the pediatrician caring for a child with

64 Ewing's sarcoma is a highly malignant bone tumor found in children and adolescents, and the or

65 s who underwent RFA of primary or metastatic bone tumors from January 2008 to April 2018.

66 Histopathological analyses of bone tumors generated by PDGF-D-expressing LNCaP cells (

67 D in human PCa LNCaP cells leads to enhanced bone tumor growth and bone responses in immunodeficient

68 Finally, enhancement of bone tumor growth in the absence of CXCR4 was abrogated

69 d apoptosis in 2 in vivo syngeneic models of bone tumor growth in which apoptosis-inducible prostate

70 Bone tumor growth inhibition with the combination as mea

71 tion treatment significantly inhibited C4-2B bone tumor growth, and the results were correlated with

72 to the effects of G-CSF administration upon bone tumor growth.

73 However, its role in primary bone tumors has not been established.

74 were significantly increased for subsequent bone tumors (HR, 1.60; 95% CI, 1.03 to 2.49) and leiomyo

75 the presence of metastases, particularly in bone, tumor hypoxia and chromosomal instability (CIN).

76 alignant focal bone lesions and to propose a Bone Tumor Imaging Reporting and Data System (BTI-RADS)

77 As the second most common malignant bone tumor in children and adolescents, Ewing sarcoma is

78 Ewing sarcoma (ES) is the second most common bone tumor in children and young adults.

79 teosarcoma (OS) is the most common malignant bone tumor in children and young adults.

80 ma (OS) is the most common primary malignant bone tumor in children, and microRNA-34a (miR-34a) repla

81 rowing physes and are the most common benign bone tumor in children.

82 Osteosarcoma is the most common malignant bone tumor in children.

83 Osteosarcoma is the most common malignant bone tumor in dogs and, like its human orthologue, is ch

84 Osteosarcoma is the most prevalent bone tumor in pediatric patients.

85 Ewing sarcoma is the most lethal bone tumor in young patients and arises from primitive s

86 Osteosarcoma is the most common malignant bone tumor in young patients and remains a significant c

87 ma are the two most common primary malignant bone tumors in children and account for approximately 6%

88 nts have been developed for the treatment of bone tumors in growing children.

89 sts was sufficient to drive the formation of bone tumors, including OS, with complete penetrance.

90 KLF4 re-expression in established KLF4 null bone tumors inhibits their osteolytic effects, preventin

91 hologic fracture (P = .03) and percentage of bone-tumor interface (BTI) ablated (P = .02).

92 administration improved bone quality at the bone-tumor interface and, surprisingly, increased histol

93 ea and reduced numbers of osteoclasts at the bone-tumor interface.

94 in-6 and the p65 subunit of NF-kappaB at the bone-tumor interface.

95 ent, osteoclast numbers were elevated at the bone/tumor interface in the vehicle-treated mice compare

96 Percutaneous biopsy of primary bone tumors is safe and accurate for diagnosis and grade

97 Osteosarcoma, the most common pediatric bone tumor, is an aggressive heterogeneous malignancy de

98 eosarcoma, the most common pediatric primary bone tumor, is an aggressive malignancy with a tendency

99 of ten 5-FC-treated Tg/NCD mice had complete bone tumor killing and five of six 5-FC-treated Tg/NCD-C

100 n this cohort, the average absorbed doses in bone tumor lesions, kidneys, red bone marrow, and bone s

101 on system achieved accurate and standardized bone tumor malignancy grading.

102 larization and recruited M2-like TAMs to the bone-tumor microenvironment (bone-TME).

103 teolytic and tumor cell-driven events in the bone-tumor microenvironment.

104 h osteoclasts and are critical components of bone-tumor microenvironment; however, their function in

105 ssue (n = 303, 11.92% vs n = 56, 7.33%), and bone tumors (n = 279, 10.98% vs n = 3, 0.39%) in patient

106 rcoma (ES), the second most common malignant bone tumor of childhood.

107 In 33 patients 2-51 mo after resection of a bone tumor of the limbs, a total of 42 dynamic PET scans

108 nd Methods This retrospective study analyzed bone tumors on radiographs acquired prior to treatment a

109 ial intelligence model that assesses primary bone tumors on radiographs may assist in the diagnostic

110 segmentation, and classification of primary bone tumors on radiographs.

111 segmentation, and classification of primary bone tumors on radiographs.

112 The trial included patients with a primary bone tumor or a soft tissue sarcoma that had invaded the

113 controls were patients diagnosed with other bone tumors or nonneoplastic conditions.

114 dverse health status domain among those with bone tumors (OR, 2.1; 95% CI, 1.8-2.5; P<.001), central

115 Primary bone tumors, osteosarcomas and chondrosarcomas, derive f

116 erved in patients who presented with primary bone tumors (P = .016).

117 stantially better survival for patients with bone tumors, particularly pediatric patients.

118 Osteosarcoma is an aggressive and deadly bone tumor, primarily afflicting children, adolescents,

119 rotocol provided a powerful tool to evaluate bone tumor progression in a rat model of bone metastasis

120 of this study was to longitudinally monitor bone tumor progression using PET/MR image coregistration

121 Cryoablation of metastatic bone tumors provided rapid and durable pain palliation,

122 Conclusion Bone tumor radiofrequency ablation is safe, with a low r

123 A high percentage of pediatric gliomas and bone tumors reportedly harbor missense mutations at glyc

124 Background Standardized bone tumor reporting is crucial for consistent, risk-ali

125 gesics, quality of life, performance status, bone tumor response, and biochemical parameters were als

126 rt the complication rate and risk factors of bone tumor RFA.

127 BS findings of SAPHO syndromes and secondary bone tumors (SBT) have overlapping features, posing diag

128 PC3 and LNCaP bone tumors showed a desmoplastic stromal response, whic

129 nancies included thyroid cancer (SIR, 36.4), bone tumors (SIR, 37.1), and colorectal (SIR, 36.4), lun

130 y decreased 99mTc-MDP activity at metastatic bone tumor sites.

131 This review addresses PET/MRI of bone tumors, soft-tissue sarcoma, melanoma, and lymphoma

132 than 17.8 years (> or =28.0%) for brain and bone tumor survivors, and was sensitive to late-recurren

133 ression analysis showed that higher baseline bone tumor SUV(mean) was significantly associated with d

134 Chordoma is a rare malignant bone tumor that expresses the transcription factor T.

135 OS) is the most frequent pediatric malignant bone tumor that has a high propensity for metastases.

136 Osteosarcoma (OS) is a primary bone tumor that is most prevalent during adolescence.

137 Osteosarcoma is the bone tumor that most commonly affects children, adolesce

138 ) is a rapidly progressive primary malignant bone tumor that occurs in children and adolescents aged

139 smal bone cysts (ABC) are locally aggressive bone tumors that often feature chromosome 17p13 rearrang

140 infections after surgery for lower extremity bone tumors that required an endoprosthesis.

141 utcome and physical activity after intensive bone tumor treatment.

142 center trial included patients with solitary bone tumors undergoing (a) radiography or CT and (b) MRI

143 undred ten consecutive patients with primary bone tumors underwent biopsy with computed tomography (C

144 However, when grown in bone, tumor volume was decreased in OPG-C4-2 versus pcDN

145 Chondrosarcoma is a cartilage-forming bone tumor, well known for intrinsic resistance to chemo

146 Applications in pulmonary, renal, and bone tumors were also discussed.

147 Of these patients, benign bone tumors were better defined with surgical specimens

148 ors were primarily osteolytic, whereas LNCaP bone tumors were both osteoblastic and osteolytic.

149 Benign or malignant bone tumors were diagnosed in all patients by using the

150 PC3 and DU145 bone tumors were primarily osteolytic, whereas LNCaP bon

151 Bone tumors were subcultured, and chromosomal analysis d

152 Additional DNA samples from bone tumors were then analysed.

153 L-1R are significantly less prone to develop bone tumors when inoculated in the arterial circulation

154 Chondrosarcoma is a primary bone tumor with a dismal prognosis; most patients with t

155 Osteosarcoma is a common malignant bone tumor with a propensity to metastasize to the lungs

156 Chordoma is a rare bone tumor with an unknown etiology and high recurrence

157 traits associated with Ewing Sarcoma, a rare bone tumor with peak onset in adolescence, among 754 tra

158 ice develop osteosarcoma (OS), an aggressive bone tumor with poor prognosis that often metastasizes t

159 Osteosarcoma is the most frequent primary bone tumor with poor prognosis.

160 Osteosarcomas (OSs) are aggressive bone tumors with many divergent histologic patterns.

161 f treated animals had complete regression of bone tumors with no development of lytic bone lesions.

162 Osteosarcoma is the most common primary bone tumor, with metastatic disease responsible for most

163 Inhibiting HER2 expression in bone tumor xenografts reduced proliferation and RANK exp

164 Osteosarcoma is the most common primary bone tumor, yet there have been no substantial advances